{
    "symbol": "IPHA",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-23 15:13:08",
    "content": " As we turn to monalizumab, we were very pleased to see our partner AstraZeneca progress to Phase 3, with the PACIFIC-9 trial in the Stage III unresectable non small cell lung cancer and the further Phase 2 study NeoCOAST-2 in the neoadjuvant setting of non small cell lung cancer. Based on the AstraZeneca sponsored Phase 2 COAST data, AstraZeneca commenced PACIFIC-9 a Phase 3 trial, evaluate the combination of either mon or oleclumab plus durvalumab in the unresectable Stage 3 non-small cell lung cancer setting who have not progressed after concurrent chemoradiation therapy. Number two, our partnership strategy continues to evolve with Sanofi doubling down on the ANKET platform with the second deal announced in December last year, and several programs now in early development. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open."
}